Triamcinolone‐impregnated nasal dressing following endoscopic sinus surgery: A randomized, double‐blind, placebo‐controlled study

Côté, David; Wright, Erin D.

doi:10.1002/lary.20905

Cited by 108 publications

(90 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Devices designed to counteract the tendency for scarring and synechiae formation are ubiquitous and include stents, packing, sponges, and gels. [4][5][6][7] All were conceived in an attempt to enhance surgical success.…”

mentioning

confidence: 99%

Safety and efficacy of a novel bioabsorbable, steroid‐eluting sinus stent

Murr

Smith

Hwang

et al. 2011

Int Forum Allergy Rhinol

161

240

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Safety and efficacy of a novel bioabsorbable, steroid‐eluting sinus stent

Murr

Smith

Hwang

et al. 2011

Int Forum Allergy Rhinol

161

240

View full text Add to dashboard Cite

show abstract

“…The addition of steroid to off-the-shelf sinus spacers is an offlabel alternative that has been attempted in an effort to position the drug in proximity to the sinuses. Such devices include balloontype sinus spacers filled with steroid (e.g., Relieva Stratus™, Acclarent Inc.) [23,24] and sinus packing material soaked with steroid [25]. In addition to the absence of randomized, controlled, multicenter clinical trials, other notable limitations to these approaches include significant variability in the possible drug dose and unknown release duration.…”

Section: Alternative Devicesmentioning

confidence: 99%

The PROPEL™ steroid-releasing bioabsorbable implant to improve outcomes of sinus surgery

Kennedy¹

2012

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Chronic rhinosinusitis is widely recognized as one of the most common chronic disease entities. Since its introduction in the USA in 1985, the role of functional endoscopic sinus surgery as an adjunct to medical therapy in the treatment of chronic sinus disease has expanded significantly. Corticosteroids are an integral part of the management of the mucosal inflammation in chronic rhinosinusitis, and it is generally accepted that existing routes of delivery to the sinus mucosa are suboptimal. The PROPEL™ steroid-releasing implant (Intersect ENT) initiates a new era in topical therapy providing controlled drug delivery directly to the sinus tissue. The mometasone furoate-releasing implant has been clinically proven to prevent obstruction of the ethmoid sinus following surgery and recently received US FDA approval. Initial studies demonstrate improved postoperative healing with the device, thus reducing the need for additional surgical procedures such as adhesion lysis and systemic steroids.

show abstract

“…Perhaps even more important, persistent inflammation presenting as mucosal edema, polypoid mucosal change, or persistent polyps will also compromise results 10,11. Several intraoperative techniques have been utilized to prevent complications, including placement of packing, stents, sponges, and gels 12–15. However, none of these devices are FDA-approved for the administration of local medications.…”

Section: Obstacles In Treating Chronic Rhinosinusitismentioning

confidence: 99%

Mometasone implant for chronic rhinosinusitis

Wei¹,

Kennedy²

2012

MDER

View full text Add to dashboard Cite

The Propel mometasone-eluting stent (Intersect ENT, Palo Alto, CA) is the first Food and Drug Administration-approved device for delivering steroid medication into the ethmoid cavity following surgery. The implant is composed of a biodegradable polymer in a lattice pattern that expands in a spring-like fashion to conform to the walls of a dissected ethmoid cavity and contains a total of 370 μg of mometasone furoate designed for gradual release over 30 days. The purpose of this article is to review the mode of action and the evidence supporting the efficacy of this novel technology. Three recently published clinical trials have demonstrated that the mometasone-eluting stent produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions. In addition, the implant has been found to significantly reduce the need for postoperative administration of oral steroids and to decrease the frequency of postoperative lysis of adhesions. Minimal adverse effects were reported in these trials and included infection, crusting, and granulation tissue formation. Although the placement of steroid-impregnated packing, stents, sponges, and gels has previously been used in the postoperative sinus cavities, the Propel mometasone-eluting stent introduces a new mechanism for localized and controlled delivery of topical therapy directly to the nasal mucosa for chronic rhinosinusitis.

show abstract

Triamcinolone‐impregnated nasal dressing following endoscopic sinus surgery: A randomized, double‐blind, placebo‐controlled study

Abstract: Data analysis suggests a significant improvement in early postoperative healing in nasal cavities receiving triamcinolone-impregnated absorbable nasal packing following ESS and is also associated with improved healing up to 6 months postoperatively.

Cited by 108 publications

References 12 publications

Safety and efficacy of a novel bioabsorbable, steroid‐eluting sinus stent

Safety and efficacy of a novel bioabsorbable, steroid‐eluting sinus stent

The PROPEL™ steroid-releasing bioabsorbable implant to improve outcomes of sinus surgery

Mometasone implant for chronic rhinosinusitis

Contact Info

Product

Resources

About